Autolus Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AUTL research report →
Range $7.6 – $11
Price Chart
About the company
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL.
- CEO
- Christian Martin Itin
- IPO
- 2018
- Employees
- 752
- HQ
- London, GL, GB
Get TickerSpark's AI analysis on AUTL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $241.65M
- P/E
- -0.94
- Fwd P/E
- 8.64
- PEG
- 0.04
- P/S
- 1.76
- P/B
- 8.82
- EV/EBITDA
- -0.73
- Div Yield
- 0.00%
- Gross Margin
- 35.77%
- Op Margin
- -159.57%
- Net Margin
- -186.32%
- ROE
- -263.11%
- ROIC
- -51.10%
Latest fiscal year · YoY change
- Revenue
- $75.56M+646.7%
- Gross Profit
- $-21,030,029+83.9%
- Op Income
- $-281,437,148
- Net Income
- $-288,199,915-30.6%
- EPS
- $-1.08-24.1%
- OCF Growth
- -37.5%
- FCF Growth
- -28.9%
- 52W High
- $2.58
- 52W Low
- $0.90
- 50D MA
- $1.62
- 200D MA
- $1.65
- Beta
- 2.35
- RSI (14)
- 17
- Avg Volume
- 2.05M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Autolus posted another strong AUCATZYL quarter, raised 2026 revenue guidance to at least $150 million, and said improved manufacturing efficiency is driving positive gross margin and a cash runway into 2Q28.· November 10, 2026
- Q3 net product revenue was $41.2 million, up 95% from $21.1 million a year ago; year-to-date sales were $113.1 million, up 122%.
- Full-year 2026 AUCATZYL net product revenue guidance was raised to at or above $150 million from the prior $140 million to $150 million range.
- Gross margin improved to 57% in Q3 from 55% in Q2 and from negative gross margin in Q3 2025; year-to-date gross margin was 44%.
- Center onboarding is ahead of plan, with 90 U.S. centers and 18 U.K. centers authorized; management said 80 U.S. centers cover roughly 80% of patients.
- Cash, cash equivalents and marketable securities were $248.4 million at September 30, 2026, and the company expects funding into 2Q28 based on current plans and financing assumptions.
Q3 2026 net product revenue was $41.2 million, compared with $21.1 million in Q3 2025, up 95% year over year. First nine months 2026 net sales were $113.1 million, up 122% versus the first nine months of 2025. Gross margin was 57% in Q3 2026 versus 55% in Q2 2026 and negative gross margin in Q3 2025; year-to-date gross margin was 44%. Cost of sales was $17.9 million, down from $28.6 million a year ago. R&D was $30.9 million versus $27.9 million; SG&A was $35.9 million versus $36.3 million. Loss from operations was $43.5 million versus $71.6 million, and net loss was $55.1 million versus $79.1 million. Cash, cash equivalents and marketable securities were $248.4 million at September 30, 2026, up from $201.6 million at June 30, 2026. Management now expects full-year 2026 AUCATZYL net product revenue for the U.S. and U.K. combined to be at or above $150 million. They also said cash should fund operations into the second quarter of 2028, assuming current operating plans, anticipated sales, and financing assumptions including the second $25 million tranche from Perceptive.
Christian Itin emphasized execution, saying the company had a strong quarter and is tracking ahead of its commercial goals. He highlighted physician experience, expanding center access, and manufacturing efficiency as the main drivers of revenue and margin progress. On the pipeline, he framed AUCATZYL expansion in ALL as the core priority while continuing lupus and progressive MS studies, but said the team wants to wait for more mature data before making major development claims in MS.
Rob Dolski focused on the improving financial profile: Q3 revenue of $41.2 million, gross margin of 57%, lower cost of sales at $17.9 million, and narrower losses versus last year. He said cash and investments totaled $248.4 million at quarter-end, boosted by the Perceptive credit facility, including an initial $75 million tranche and assumptions tied to a second $25 million tranche. Based on those assumptions and current plans, he said the company expects to fund operations into 2Q28.
Analysts pressed on why Autolus is waiting for 12 months of follow-up in progressive MS, and management said KOL feedback was consistent that EDSS stabilization with less than 12 months of follow-up is not yet interpretable and may not show true disease arrest. They also asked whether the BOBCAT study size increase to 24 patients reflected concern about the original 18-patient plan; management said the added patients and use of both Flu/Cy and bendamustine should give a better read on efficacy and that enrollment is going well. Other questions focused on lupus safety, sales seasonality, and gross margin trajectory; management said lupus safety has looked favorable so far, holiday timing may slow Q4 dosing, and margins should keep improving gradually rather than in a step change.
The quarter showed strong commercial momentum: AUCATZYL sales nearly doubled year over year, guidance moved higher, and center activation was ahead of plan. Management also pointed to better manufacturing efficiency, a 57% Q3 gross margin, and a longer cash runway, which supports the idea that the business is moving closer to self-sustaining economics.
Management acknowledged that Q4 can be seasonally softer because of Thanksgiving and year-end holidays, and said sales growth could look flatter quarter to quarter even after a strong year. In MS, they are deliberately delaying the first readout until there is longer follow-up, which pushes out potential development clarity and registrational decision-making. They also noted lupus has been a difficult category for cell therapy and that patient enrollment there is generally less robust than in MS.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.4%
- Shares Outstanding
- 266.34M
- Float Shares
- 240.69M
of shares held by institutions
86 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mak Capital One LLC | 33.62M | 0 |
| Blackstone Inc. | 20.49M | 0 |
| Syncona Portfolio Ltd | 16.64M | 0 |
| Armistice Capital, LLC | 15.00M | ▼ 800.00K |
| Tetragon Partners Gp Ltd | 9.50M | 0 |
| Schroder Investment Management Group | 7.83M | ▼ 1.66M |
| Frazier Life Sciences Management, L.P. | 4.45M | 0 |
| Bnp Paribas Asset Management Holding S.A. | 3.36M | 0 |
| Laurion Capital Management LP | 3.32M | 0 |
| Renaissance Technologies LLC | 2.49M | ▲ 508.20K |
| Morgan Stanley | 2.11M | ▲ 844.70K |
| Bank Of America Corp | 1.61M | ▼ 239.58K |
Held by 23 ETFs
Biggest fund positions in AUTL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 1, 26 | Piccina Cintia | other | 20,000 |
| Sep 1, 26 | Piccina Cintia | other | 20,000 |
| Sep 2, 26 | Piccina Cintia | sell | 6,713 |
| Jun 29, 26 | YOUNG WILLIAM D | other | 47,500 |
| Jun 29, 26 | YOUNG WILLIAM D | other | 31,667 |
| Jun 29, 26 | Rao Madduri Ravin | other | 47,500 |
| Jun 29, 26 | Rao Madduri Ravin | other | 31,667 |
| Jun 29, 26 | Richardson Ryan | other | 47,500 |
| Jun 29, 26 | Richardson Ryan | other | 31,667 |
| Jun 29, 26 | Leiderman Elisabeth | other | 47,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AUTL coverage
Recent articles, reports, and earnings notes.
Want a deeper read on AUTL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
globenewswire.com · Nov 10
Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Autolus Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 10
Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
globenewswire.com · Nov 10
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference
globenewswire.com · Nov 9
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
globenewswire.com · Nov 4
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 3
Autolus Therapeutics: Key Questions For The Near Term
seekingalpha.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
